Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
Sponsor: INIBIO Co., Ltd.
Summary
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
Official title: A Multi-center, Double-blind, Randomized, Parallel, Active-controlled Phase III Trial to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
Key Details
Gender
All
Age Range
19 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
292
Start Date
2021-05-27
Completion Date
2022-03-05
Last Updated
2026-06-02
Healthy Volunteers
Yes
Conditions
Interventions
Botulinum Toxin Type A Injection [INI101]
Single administration, Day 0, 20 units
Botulinum Toxin Type A Injection [Botox]
Single administration, Day 0, 20 units
Locations (1)
INIBIO Co., Ltd.
Bucheon-si, Gyeonggi-do, South Korea